NCT04013217: Evaluate Eribulin ORA in Subjects With Solid Tumors

NCT04013217
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic or uncontrolled brain metastases requiring current treatment
https://ClinicalTrials.gov/show/NCT04013217

Comments are closed.

Up ↑